Pasiego del Pas
10/08/20 22:20
Ha respondido al tema
Novavax (NVAX): Un Nuevo Comienzo
Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD, and OWSExpanded large scale global manufacturing capacity through acquisition and partneringCompany to host conference call today at 4:30 p.m. ETNovavax reported a net loss of $17.5 million, or $0.30 per share, for the second quarter of 2020, compared to a net loss of $39.6 million, or $1.69 per share, for the second quarter of 2019. For the six months ended June 30, 2020, the net loss was $43.4 million, or $0.84 per share, compared to a net loss of $82.8 million, or $3.77 per share, for the same period in 2019.Novavax revenue in the second quarter of 2020 was $35.5 million, compared to $3.4 million in the same period in 2019. This significant increase was due to increased development activities relating to NVX-CoV2373 under the CEPI agreement.https://finance.yahoo.com/news/novavax-reports-second-quarter-2020-200200678.html?_guc_consent_skip=1597090664